Contact this trialFirst, we need to learn more about you.
Antimetabolite
Ivosidenib + Chemotherapy for Acute Myeloid Leukemia
Recruiting3 awardsPhase 1
Chicago, Illinois
This trial is studying the side effects and best dose of ivosidenib when given with combination chemotherapy to treat patients with 1DH1 mutant acute myeloid leukemia that has come back or does not respond to treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.